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Abstract
Introduction: Evidence indicates that rheumatoid arthritis (RA) patients have increased susceptibility to myocardial
ischaemia that contributes to myocardial infarction. The subendocardial viability ratio (SEVR) can be measured
using pulse wave analysis and reflects myocardial oxygen supply and demand. The objective of the present study
was to examine specific predictors of SEVR in RA patients, with a specific focus on inflammation and classical
cardiovascular disease (CVD) risk factors.
Methods: Two patient cohorts were included in the study; a primary cohort consisting of 220 RA patients and a
validation cohort of 127 RA patients. All patients underwent assessment of SEVR using pulse wave analysis.
Thirty-one patients from the primary cohort who were about to start anti-inflammatory treatment were
prospectively examined for SEVR at pretreatment baseline and 2 weeks, 3 months and 1 year following treatment.
Systemic markers of disease activity and classical CVD risk factors were assessed in all patients.
Results: The SEVR (mean ± standard deviation) for RA in the primary cohort was 148 ± 27 and in the validation
cohort was 142 ± 25. Regression analyses revealed that all parameters of RA disease activity were associated with
SEVR, along with gender, blood pressure and heart rate. These findings were the same in the validation cohort.
Analysis of longitudinal data showed that C-reactive protein (P < 0.001), erythrocyte sedimentation rate (P < 0.005),
Disease Activity Score in 28 joints (P < 0.001), mean blood pressure (P < 0.005) and augmentation index (P < 0.001)
were significantly reduced after commencing anti-TNFa treatment. Increasing C-reactive protein was found to be
associated with a reduction in SEVR (P = 0.02) and an increase in augmentation index (P = 0.001).
Conclusion: The present findings reveal that the SEVR is associated with markers of disease activity as well as
highly prevalent classical CVD risk factors in RA, such as high blood pressure and diabetes. Further prospective
studies are required to determine whether the SEVR predicts future cardiac events in RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
musculoskeletal disease that affects ~0.8% of the adult
population. RA also associates with an increased risk for
cardiovascular disease (CVD) [1], which is only partially
explained by traditional CVD risk factors [2]. The
inflammatory processes of RA and CVD are remarkably
similar, suggesting that RA itself may be an important
risk factor for CVD [3].
The leading cause of cardiac death in RA is myocardial
infarction [4]. A study in RA patients without overt cor-
onary artery disease reported abnormalities in myocardial
perfusion using contrast-enhanced magnetic resonance
imaging (cMRI), and the degree of abnormality was
related to the extent of RA disease-related inflammation
[5]. In another study, RA patients undergoing coronary
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angiography had greater myocardial ischaemia than
healthy controls who were matched for classical CVD
risk factors, but had similar levels of ischaemia to age-
matched and sex-matched diabetic controls [6]. Further-
more, myocardial ischaemia was evident despite the
absence of obstructive coronary artery disease, suggesting
a microvascular cause for the ischaemia [6].
The current gold standard measure of microvascular
coronary perfusion is coronary angiography; however, this
procedure is invasive, carries considerable risk to the
patient and cannot be repeated at regular intervals. Arter-
ial tonometry using pulse wave analysis has recently
gained interest in clinical research as it can non-invasively
measure the central aortic pressure waveform and yield
information on the augmentation index (AIx) (arterial
stiffness), ejection duration (duration of ventricular con-
traction), pulse pressure (PP; pressure generated by the
left ventricle during systole), mean blood pressure (MBP;
product of cardiac output and systemic vascular resis-
tance), tension time index (TTI; pressure load during sys-
tole), diastolic time index (DTI; pressure load during
diastole) and subendocardial viability ratio (SEVR; a mea-
sure of coronary microvascular perfusion) [7].
In particular, the SEVR reflects myocardial oxygen sup-
ply and demand, with low values representing a lesser
degree of myocardial perfusion [8]. The ratio of DTI ver-
sus TTI (that is, the integral of pressure and time during
diastole and systole, respectively) has been shown to corre-
late well with the ratio of subepicardial to subendocardial
blood flow, and therefore represents an index of subendo-
cardial viability, defined as the SEVR (Buckberg index)
[9,10]. The SEVR is an independent predictor of coronary
flow reserve in patients with essential hypertension [11],
and is related to coronary artery calcification in patients
with diabetes [12]. In addition, low SEVR associates with
severity of diabetes [13], poor renal function [14], low phy-
sical fitness [15], and cigarette smoking [16]. As such, the
SEVR can be utilised as a surrogate measure of coronary
microvascular perfusion in a number of different clinical
populations.
To our knowledge only two studies have examined the
SEVR in patients with RA [17,18]; one small pilot study
revealed that the SEVR improved following 12 months of
lipid-lowering treatment when compared with a group
receiving only a placebo drug [17], while in another study
the SEVR was worse following 7 weeks of anti-inflamma-
tory treatment in RA and ankylosing spondylitis patients
[18]. However, the small sample sizes of both studies, as
well as the inclusion of different patient groups in the lat-
ter study, make these findings difficult to interpret.
The aims of the present study were: to examine asso-
ciations between disease-related inflammation and classi-
cal CVD risk factors with SEVR in two separate cohorts
of RA patients; and to prospectively assess the long-term
effects of anti-inflammatory treatment on SEVR.
Materials and methods
Patients
Two hundred and twenty consecutive RA patients were
recruited from the rheumatology outpatient clinics of the
Dudley Group of Hospitals NHS Trust, UK and formed the
primary cohort. A separate validation cohort consisting of
127 consecutive RA patients were recruited from the rheu-
matology outpatient clinics of the First Department of
Propaedeutic and Internal Medicine, Laikon Hospital,
Greece. All patients met the retrospective application of the
1987 revised RA criteria of the American College of Rheu-
matism [19]. Patients were excluded if they had previously
confirmed acute coronary syndrome, established CVD or
serious psychiatric disorder as indicated in their medical
notes and/or on questioning during the initial consultation.
The study received ethics approval from Birmingham, East,
North and Solihull Research Ethics Committee and all par-
ticipants gave their written informed consent according to
the Declaration of Helsinki.
Protocol
Patients reported to a temperature-controlled vascular
laboratory (22 to 24°C) after a 12-hour overnight fast.
Patients from both cohorts underwent a detailed clinical
examination, which included evaluation of their medical
history and hospital records, and assessment of their height
and weight, as well as calculation of their body mass index.
In addition, demographic information was collected from
all patients by questionnaire. The Disease Activity Score in
28 joints (DAS28) [20] and the Anglicised version of the
Stanford Health Assessment Questionnaire [21] were com-
pleted in the primary cohort only. Blood pressure measure-
ments were taken using an automated blood pressure
monitor - Datascope Accutor (Montvale, New Jersey, USA)
and Microlife WatchBP Office (Widnau, Switzerland) for
the primary and validation cohorts, respectively - after the
patients had rested for 20 minutes. A blood sample was
also obtained. Following this, the participants underwent
assessment of the SEVR using pulse wave analysis.
Blood sampling
Serum from patients in the primary cohort was analysed
for total cholesterol, high-density lipoprotein cholesterol,
triglycerides, C-reactive protein (CRP) and glucose using
a Vitros® 5.1 FS Chemistry system (Ortho Clinical, High
Wycombe, Bucks, UK). The Westergren erythrocyte sedi-
mentation rate (ESR) was measured using the Starrsed
Compact (Mechatronics BV, Hoorn, the Netherlands).
All tests were carried out in the routine and research
laboratories of Russells Hall Hospital, Dudley Group
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NHS Foundation Trust, UK. In the validation cohort,
only CRP was measured using a Vitros® 5.1 FS Chemistry
system in the routine laboratory of Laikon Hospital,
Greece.
Pulse wave analysis
Pulse wave analysis (SphygmoCor Px Pulse Wave Analysis;
ScanMed Medical Instruments, Moreton in Marsh, UK)
was used to determine the SEVR, AIx, PP, MBP, TTI, and
DTI. After recording the brachial blood pressure, the left
radial artery was palpated to identify a suitable pulse. The
applanation tonometer was positioned over the artery with
enough pressure to flatten (but not occlude) the patient’s
radial artery. The applanation tonometer detects the PP
wave, which is calibrated against the standard brachial
blood pressure and gives the maximum (systolic) and
minimum (diastolic) points of the pressure wave. The
pressure waveform is then mathematically transformed
into a central aortic waveform that contains the first (peak
flow) and second (peak pressure) systolic peaks and dis-
plays information on ejection duration.
The SEVR is calculated by utilising the ejection duration
that is automatically measured by the Sphygmocor system
and dividing the area under the diastolic curve (coronary
perfusion) by the area under the systolic curve (cardiac
workload). In normal conditions, the SEVR can be any-
where between 130 and 200%. Values that are below unity
(100%) reflect poor perfusion of the subendocardium [8].
The AIx is calculated as the difference between the second
and first systolic peaks and is expressed as a percentage of
the PP, with a high value indicating greater arterial stiff-
ness. The pressure waveforms in the radial artery were
recorded for an 11-second period. The software integrated
in the analyser displayed an operator index that reflects
the quality of the recorded waveform. If the operator
index was low (< 75), another reading was taken. Three
readings with an operator index > 75 were used for analy-
sis. For each parameter, the average of three readings was
calculated. Owing to some loss of data, PP was only avail-
able for 147 patients from the primary cohort.
Longitudinal study cohort
Thirty-one patients from the primary cohort who were
about to start anti-inflammatory treatment (anti-TNFa,
n = 21), intravenous glucocorticoids (n = 6), and rituximab
(n = 4) on clinical indication (UK guidelines) were
recruited into a 1-year prospective study. All of the assess-
ments described above were conducted before patients
started treatment (pretreatment baseline), and repeated at
2 weeks, 3 months and 1 year after initiation of treatment.
For patients starting on anti-TNFa, assessments at 2
weeks and 3 months were performed before receiving the
next dose of their anti-TNFa drug.
Statistical analysis
Cross-sectional study
Statistical analysis was performed using SPSS18 (SPSS Inc.,
Chicago, IL, USA). Variables were tested for normality by
the Kolmogorov-Smirnov test. Log transformation was
performed for positively skewed variables as appropriate.
Values are expressed as the mean (standard error), geo-
metric mean (95% confidence interval), median (25th to
75th percentile values) or percentages, as appropriate. Uni-
variate analysis of variance was used to assess differences
in the SEVR (dependent variable) according to gender,
presence of CVD risk factors, medication use and rheuma-
toid factor positivity (fixed factors). To identify specific
determinants of the SEVR in RA, linear regression (contin-
uous variables) and logistic regression (discontinuous vari-
ables) were used. The SEVR was entered as the dependent
variable, and demographic, CVD risk factors and inflam-
matory variables were entered separately as independent
variables.
Longitudinal study
The longitudinal data were analysed using generalised esti-
mating equations. This allowed for the potential correla-
tions between repeated measurements made on the same
patients to be adjusted for. To consider the effect of the
anti-inflammatory treatment, separate models were pro-
duced for each of the outcomes considered, which were
log10-transformed prior to the analysis, where applicable.
The measurement time was entered as a factor in each
model, with the baseline value set as the reference cate-
gory. An unstructured correlation structure was used
where possible, since this is the most general option, with
exchangeable structures used where convergence was not
achieved.
CRP and the ESR were then included separately as
factors in these models. This separate inclusion allowed
for the effect each of these factors on the other out-




The patient characteristics for both cohorts are presented
in Table 1. The majority of patients were female and had
low to moderate disease activity levels.
Effects of medications on the subendocardial
viability ratio
Univariate analysis of variance showed that the SEVR did
not differ between patients receiving or not receiving ster-
oid treatment in both the primary and validation cohorts.
This was a similar finding for disease-modifying anti-rheu-
matic drug use, biologic agents, antihypertensives, anti-
hypercholesterolemics, nonsteroidal anti-inflammatory
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Table 1 Characteristics and pulse wave analysis for rheumatoid arthritis patients in both cross-sectional and
longitudinal cohorts
Rheumatoid arthritis patients
Primary cohort (n = 220) Validation cohort (n = 127) Longitudinal cohort (n = 31)
Age (years) 61 ± 12 59 ± 13 53 ± 13
Sex female 176 (80) 103 (81) 21 (68)
Disease-related characteristics
Disease duration (years) 17 ± 12 10 ± 10 13 ± 13
Rheumatoid factor-positive (%) 126 (79) n/a 23 (74)
Erythrocyte sedimentation rate (mm/hour) 12 (7 to 26) 22 (12 to 38) (n = 112) 10 (4 to 16)
C-reactive protein (mg/l) 3 (3 to 12) 5 (3 to12) 18 (9 to 33)
DAS28 3.29 ± 1.26 n/a 4.32 ± 0.87
HAQ 1.6 ± 0.9 n/a 2.19 ± 0.42
Classical CVD risk factors
Body mass index 29 ± 6 33 ± 12 29 ± 6
Current smokers 33 (15) 40 (31) 7 (23)
Diabetes mellitus 17 (8) 10 (8) 0 (0)
Dyslipidaemia 60 (27) 30 (24) 7 (23)
SBP (mmHg) 134 ± 18 134 ± 18 130 ± 14
DBP (mmHg) 79 ± 11 79 ± 10 81 ± 11
Heart rate (beats/minute) 74 ± 13 68 ± 11 73 ± 12
Total cholesterol (mmol/l) 5.0 ± 1.0 5.2 ± 0.9 (n = 114) 5.0 ± 0.9
HDL (mmol/l) 1.5 ± 0.4 1.6 ± 0.7 (n = 102) 1.5 ± 0.3
Triglycerides (mmol/l) 1.3 ± 0.6 1.2 ± 0.4 (n = 95) 1.5 ± 0.6
TC:HDL ratio 3.5 ± 1.1 3.5 ± 0.8 (n = 102) 3.5 ± 0.8
RA disease-specific medications
Methotrexate 124 (65) 76 (60) 19 (61)
Sulfasalazine 44 (24) 0 5 (16)
Hydroxychloroquine 50 (28) 0 4 (13)
Leflunomide 15 (9) 16 (13) 0 (0)
Prednisolone 48 (26) 85 (67) 6 (19)
NSAID 34 (20) 3 (2) 6 (19)
COX II inhibitors 12 (7) 0 (0) 2 (7)
Analgesic 74 (40) n/a 8 (26)
Folic acid 118 (63) 63 (50) 16 (52)
Anti-TNFa 44 (20) 51 (40) –
CVD medications
Anti-hypertensive 67 (36) 68 (66) 6 (19)
Anti-hypercholesterolemics 57 (31) 23 (18) 4 (13)
Beta-blocker 20 (11) 28 (22) 2 (7)
Calcium channel-blocker 24 (14) 19 (15) 0 (0)
Pulse wave analysis
Ejection duration (m/second) 312 ± 27 331 ± 26 320 ± 25
Pulse pressure (mmHg)b 46 ± 13a 54 ± 14 -
Mean pressure (mmHg) 99 ± 12 97 ± 11 99 ± 10
Tension time index 2,424 ± 402 2,485 ± 441 2,359 ± 368
Diastolic time index 3,493 ± 462 3,443 ± 472 3,523 ± 651
SEVR (%) 148 ± 27 142 ± 25 157 ± 33
Augmentation index (%) 33 ± 9 34 ± 10 32 ± 9
Results expressed as number (percentage), median (25th to 75th percentile values) or mean ± standard deviation. COX, cyclooxygenase; CVD, cardiovascular
disease; DAS28, Disease Activity Score in 28 joints; DBP, diastolic blood pressure; HAQ, Health Assessment Questionnaire; HDL, high-density lipoprotein; n/a, not
available; NSAID, nonsteroidal anti-inflammatory drug; SBP, systolic blood pressure; SEVR, subendocardial viability ratio; TC, total cholesterol. aData only available
for 147 patients. bData unavailable for longitudinal cohort.
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drugs, and cyclooxygenase II inhibitors. However, the
SEVR was higher in patients receiving b-blockers in the
primary cohort only (167 ± 24 vs. 146 ± 27, P < 0.01).
Effects of CVD risk factors on the subendocardial
viability ratio
Univariate analysis of variance was used to compare SEVR
levels in patients with and without classical CVD risk fac-
tors. This analysis revealed that patients with diabetes had
significantly lower SEVR than nondiabetic patients (127 ±
19 and 149 ± 26 respectively, P < 0.001). There was no dif-
ference in SEVR for any of the other CVD risk factors.
Similar findings were also apparent in the validation
cohort, except that the SEVR between diabetic and non-
diabetic patients did not reach statistical significance
(133 ± 31 and 142 ± 24 respectively, P = 0.28).
Univariate predictors of the subendocardial viability ratio
Linear and binary regression analysis was performed to
determine univariate predictors (independent variable) of
the SEVR (dependent variable) in patients with RA (see
Table 2). This analysis revealed that gender was associated
with the SEVR in the primary cohort, with females having
lower SEVR than males (144 ± 25 and 162 ± 28 respec-
tively, P < 0.001). Similarly, gender was also associated with
the SEVR in the validation cohort; with females having a
lower SEVR than males (139 ± 25 and 151 ± 24 respec-
tively, P = 0.04). From the disease-related variables, log
ESR and log CRP were inversely associated with the SEVR,
and a positive association was found with log disease
duration in patients in the primary cohort (Table 2). Only
PP and heart rate were inversely associated with the SEVR
from the classical CVD risk factors. However, there were
trends for an inverse association between body mass index,
total cholesterol and SEVR. In the validation cohort, log
CRP (but not disease duration and ESR) was inversely asso-
ciated with the SEVR (Table 2). As with the primary
cohort, PP (marginally MBP) and heart rate were the CVD
risk factors associated with the SEVR.
Multivariate predictors of the subendocardial viability
ratio in the primary cohort
Stepwise multivariate regression was performed to examine
the relationship between significant univariate predictors
presented in the analysis above (independent variables) and
the SEVR (dependent variables). The individual compo-
nents that were entered into the model were gender, log
disease duration, log ESR, log CRP, PP and heart rate. The
entry probability was 0.05 and none of the variables were
forced back into the model. From this analysis a significant
model emerged (adjusted R2 = 0.631, F4, 76 = 35.3, P <
0.001). Significant variables within the model included
heart rate (b = -0.75, P <0.001), PP (b = -0.39, P <0.001),
log ESR (b = -0.29, p = 0.001) and log CRP (b = 0.18,
P = 0.03).
Multivariate predictors of the subendocardial viability
ratio in the validation cohort
Similar multivariate regression as above was performed in
the validation cohort. The individual components that
Table 2 Regression analysis between general characteristics, disease-related characteristics, classical cardiovascular
disease risk factors and the SEVR
Primary cohort Validation cohort
General characteristics
Age b = 0.02, P = 0.79 b = 0.03, P = 0.73
Gender 0.97 (0.96 to 0.99)* 0.98 (0.96 to 0.99)*
Disease-related characteristics
Log disease duration b = 0.21, p = 0.01 b = 0.12, P = 0.21
RF positivity 0.90 (0.99 to 1.02) n/a
Log ESR b = -0.20, P = 0.01 b= -0.144, P = 0.131
Log CRP b = -0.23, P = 0.003 b = -0.28, P = 0.002
DAS28 b = -0.12, P = 0.09 n/a
HAQ b = -0.11, P = 0.16 n/a
Classical CVD risk factors
Body mass index b = - 0.13, P = 0.05 b = - 0.19, P = 0.18
Pulse pressure b = -0.23, P = 0.004 b = - 0.21, P = 0.017
Mean blood pressure b = -0.10, P = 0.15 b = -0.17, P = 0.05
Heart rate b = -0.64, P < 0.001 b = -0.76 P < 0.001
Total cholesterol b = -0.12, P = 0.09 b = -0.14, P = 0.14
TC:HDL ratio b = -0.02, P = 0.76 b = -0.09, P = 0.35
Triglycerides b = -0.01, P = 0.90 b = 0.01, P = 0.94
Data presented as b and P values or odds ratio (95% confidence interval). CRP, C reactive protein; CVD, cardiovascular disease; DAS28, Disease Activity Score in
28 joints; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HDL, high density lipoprotein; n/a, not available; RF, rheumatoid factor;
SEVR, subendocardial viability ratio; TC, total cholesterol. *P < 0.001. Bold data represent statistically significant results.
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were entered into the model as independent variables were
gender, log CRP, PP and heart rate, with the SEVR entered
as the dependent variable. From this analysis a significant
model was apparent (adjusted R2 = 0.69, F = 72.1, P <
0.001). Significant variables within the model included
heart rate (b = -0.783, P <0.001), PP (b = -0.258,
P <0.001), and gender (b = -0.249, P < 0.01). In an alterna-
tive model without heart rate, log CRP was, independently
of gender and PP, associated with the SEVR (b = -0.238,
P <0.05).
Inflammation and components of the subendocardial
viability ratio
To examine the effects of inflammation on the compo-
nents used to calculate the SEVR, further linear regression
analysis was performed with DTI, TTI and heart rate
entered separately as dependent variables, and log ESR,
log CRP as well as DAS28 entered separately as indepen-
dent variables. This analysis showed that DTI was inver-
sely associated with all parameters of disease activity, but
no such associations were apparent for TTI (see Table 3).
Heart rate was inversely associated with log ESR and log
CRP only. In the validation cohort, TTI was positively
associated with log CRP (b = 0.28, P = 0.002) while heart
rate was inversely associated with log CRP (b = -0.27, P =
0.01) (Table 3).
Longitudinal study
The effect of anti-inflammatory treatment on a range of
outcomes was considered using generalised estimating
equations (Table 4). Each outcome was considered sepa-
rately, with the time that measurements were taken
included as a categorical factor. This analysis gave an over-
all significance for the change over time, which tested the
null hypothesis that the outcome considered remained
constant for the year after the commencement of treat-
ment. There was significant evidence against this hypoth-
esis for CRP (P < 0.001), ESR (P = 0.004), DAS28 (P <
0.001), MBP (P = 0.002) and AIx (P < 0.001), with the only
nonsignificant outcome being the SEVR (P = 0.30). Hence,
for those outcomes that were significant, it can be con-
cluded that the average measurements changed over time.
To detect where these changes occurred, pairwise
comparisons were made between the baseline and all of
the subsequent measurement times. Where this was sig-
nificant, it implied that the outcome considered changed
significantly after the treatment began. As can be seen
in Table 4, in each case that a pairwise comparison was
significant, the observed mean was smaller than that at
baseline; hence, the treatment brought about a signifi-
cant reduction in these outcomes.
A secondary analysis considered the effect of CRP and
ESR on the other factors considered above (Table 5). Gen-
eralised estimating equations were again used to account
for the potential correlation between repeated measure-
ments made on the same patient. In each model, either
the CRP or ESR was entered as a continuous predictor,
with the SEVR, MBP or AIx as the dependent variable.
The resulting P value then represented the strength of the
relationship between the two variables in the model. The
coefficient demonstrated the increase in the dependent
variable that would be expected for each increase in the
predictor variable. Owing to the necessity of log transfor-
mations, this relationship was not necessarily linear.
The ESR was not found to be a significant predictor of
any of these outcomes, whilst CRP was found to have sig-
nificant effects on both the AIx (P < 0.001) and the SEVR
(P = 0.02). For the former, the resulting coefficient implied
that a 10-fold increase in CRP increases the AIx by 5.4
(95% confidence interval = 1.8 to 7.3). Because both of
these variables are log10 transformed, the relationship
between CRP and the SEVR is more complex. The model
showed that a 10-fold increase in CRP reduces the log10 of
the SEVR by 0.03 (95% confidence interval = 0.00 to 0.06).
Applying this to a real-world example, an increase of CRP
from 1 to 10 would be expected to reduce the SEVR from
174 to 162. A 10-fold increase in CRP hence reduces the
SEVR by approximately 12.
Table 3 Regression analysis between individual components of the SEVR and inflammation in the primary cohort
Log ESR Log CRP DAS28
Primary cohort
DTI b = -0.26, P = 0.001 b = -0.17, P = 0.03 b = -0.20, P = 0.004
TTI b = 0.02, P = 0.85 b = 0.13, P = 0.08 b = -0.006, P = 0.38
HR b = 0.18, P = 0.02 b = 0.32, P < 0.001 b = 0.13, P = 0.006
Validation cohort
DTI b = -0.02, P = 0.81 b = -0.053, P = 0.56 n/a
TTI b = 0.16, P = 0.10 b = 0.28, P = 0.002 n/a
HR b = 0.85, P = 0.37 b = -0.27, P = 0.01 n/a
CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; DTI, diastolic time index; ESR, erythrocyte sedimentation rate; HR, heart rate; n/a, not available;
SEVR, subendocardial viability ratio; TTI, tension time index. Bold data represent statistically significant results.
Sandoo et al. Arthritis Research & Therapy 2012, 14:R258
http://arthritis-research.com/content/14/6/R258
Page 6 of 11
Discussion
The present findings from two separate cohorts of RA
patients revealed that SEVR, a non-invasive measure of
subendocardial perfusion, is associated with disease-
related inflammation along with classical CVD risk factors
such as the heart rate, PP and diabetes. In particular, these
data generate the hypothesis that inflammation impairs
myocardial perfusion, as assessed by the SEVR, via the sti-
mulation of the autonomic nervous system; that is,
increased heart rate and especially a decrease in DTI.
Alternatively, as suggested by the validation cohort data,
the SEVR may also be reduced due to increased TTI in
the presence of higher inflammation.
Coronary artery disease is typically silent in RA, with a
greater frequency of unrecognised myocardial infarction
and sudden cardiac death [22]. This highlights the impor-
tance of identifying myocardial perfusion defects as early
as possible. Assessment of the SEVR is non-invasive, sim-
ple to perform, carries no risk to the participant and can
be repeated at regular intervals. The SEVR primarily
reflects diastolic dysfunction and plays an important role
in the development of CVD [23], and associates with inva-
sive measures of coronary microvascular function such as
coronary flow reserve [11]. In addition, the SEVR is related
to a number of clinical conditions including diabetes [13],
impaired renal function [14], low physical fitness [15],
and cigarette smoking [16]. Assessment of the SEVR thus
appears to be a valid surrogate measure of coronary
microvascular perfusion, particularly in a research setting
with healthy volunteers and in patients without overt
CVD. In a 2-year prospective study conducted by Proto-
gerou and colleagues in frail older participants exhibiting
the blood pressure J-curve phenomenon (that is, present-
ing higher mortality in the presence of low diastolic blood
pressure), the SEVR was significantly impaired in the
higher mortality group - providing further evidence that
an impaired SEVR could have an impact on CVD, inde-
pendently from other classical markers of cardiovascular
health (such as intima-media thickness, pulse wave velo-
city, left ventricular mass - all of which were similar
between the groups) [24].
The inflammatory nature of RA and CVD is strikingly
similar [3], and on this basis it has been hypothesised that
RA disease-related inflammation contributes to the excess
CVD risk present in RA [25]. The present study examined
associations between disease-related inflammation and the
SEVR in a large cohort of patients and demonstrated that
the SEVR was associated with all markers of disease
Table 4 Generalised estimating equations testing the effect of time on various measurements.
CRPa ESRa DAS28 SEVRa MBPa AIx
Significance of change over time
P value < 0.001 0.004 < 0.001 0.30 0.002 < 0.001
Baseline
Meanb 8.7 (5.7 to 13.2) 16.8 (11.3 to 25.0) 4.3 (0.17) 153.3 (142.1 to 165.5) 98.9 (95.2 to 102.8) 31.9 (1.56)
2 weeks
Meanb 4.2 (2.8 to 6.4) 10.8 (7.4 to 15.9) 2.8 (0.26) 154.8 (144.9 to 165.3) 94.4 (90.2 to 98.8) 30.2 (1.74)
P valuec < 0.001 < 0.001 < 0.001 0.69 0.010 0.11
3 months
Meanb 5.5 (3.7 to 8.3) 11.4 (6.9 to 18.9) 2.8 (0.27) 160.4 (149.6 to 172.0) 92.9 (88.0 to 98.1) 32.3 (1.98)
P valuec < 0.001 0.05 < 0.001 0.14 0.003 0.75
1 year
Meanb 2.8 (1.6 to 5.1) 11.9 (7.9 to 17.7) 2.6 (0.29) 154.1 (140.5 to 169.1) 92.7 (87.3 to 98.5) 29.6 (2.15)
P valuec < 0.001 0.33 < 0.001 0.85 0.002 0.13
AIx, augmentation index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DAS28, Disease Activity Score in 28 joints; MBP, mean blood pressure;
SEVR, subendocardial viability ratio. From a generalised estimating equation, with unstructured correlation structure. aLog10-transformed prior to analysis.
bData
displayed as geometric mean (95% confidence interval) or mean (standard error) as applicable. cVersus baseline. Bold data represent statistically significant
results.
Table 5 Generalised estimating equations testing effect of CRP and ESR on SEVR, MBP and augmentation index
Outcome Effect of CRPa Effect of ESRa
Coefficient (95% CI) P value Coefficient (95% CI) P value
SEVRa -0.031 (-0.059 to -0.004) 0.02 -0.028 (-0.079 to 0.023) 0.28
MBPa 0.009 (-0.009 to 0.026)b 0.34b -0.009 (-0.033 to 0.015)b 0.48b
AIx 5.434 (1.769 to 7.299) 0.001 -1.887 (-4.877 to 1.104) 0.22
AIx, augmentation index; CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MBP, mean blood pressure; SEVR, subendocardial
viability ratio. From a generalised estimating equation, with unstructured correlation structure, unless stated otherwise. aLog10-transformed prior to analysis.
bExchangeable correlation structure used.
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activity and inflammation (DAS28, ESR and CRP).
Furthermore, although there was no evidence that SEVR
changed significantly in response to anti-inflammatory
treatment in the longitudinal study, the latter analysis
found a significant negative relationship between CRP and
SEVR (P = 0.02). The results of the model showed that a
10-fold increase in CRP is associated in a reduction of
0.031 in the log10 SEVR. To our knowledge only one other
study, with a small sample size of RA patients (n = 17),
has assessed the effects of inflammation on the SEVR in
RA, and revealed that the SEVR was worse following 7
weeks of treatment with anti-TNFa despite a reduction in
disease activity and inflammation [18]. However, the find-
ings of that study need to be interpreted with caution as
the treatment group also consisted of 13 ankylosing spon-
dylitis patients, and analysis was performed by categorising
the RA patients and ankylosing spondylitis patients into
one group. In addition, the reduction in SEVR following
treatment (ΔSEVR 7.4%) was smaller than the nonsignifi-
cant difference in SEVR between patients and healthy con-
trols at baseline (ΔSEVR 10.1%), thus limiting the clinical
relevance of this finding [18].
Studies assessing coronary microvascular function con-
sistently demonstrate inflammation to be an important
contributor to myocardial ischaemia. For example,
Kobayashi and colleagues demonstrated myocardial perfu-
sion defects in RA patients using cMRI [5]. Furthermore,
they reported that abnormal cMRI was associated with
higher DAS28, and patients with impaired cMRI had sig-
nificantly higher levels of ESR and CRP than patients with
normal cMRI [5]. Another study in RA revealed that myo-
cardial perfusion defects were as a result of abnormalities
in the coronary microvasculature and that this was asso-
ciated with high disease activity [6]. These cross-sectional
findings suggest that inflammation might more readily
affect microvascular function, rather than macrovascular
function, but further prospective studies specifically exam-
ining this hypothesis are warranted.
In the present work, inflammation was inversely asso-
ciated with DTI and positively associated with heart rate.
These findings suggest that inflammation may lower the
time for diastolic filling of the heart while simultaneously
increasing cardiac workload due to an elevated heart rate.
Both of these actions would have a negative impact on
cardiac perfusion and contribute to myocardial ischaemia,
especially as the heart rate was inversely associated with
the SEVR in multivariate analysis. Inflammation therefore
appears to have a detrimental association with myocardial
ischaemia, possibly due to negative actions on cardiac per-
fusion and workload. Alternatively, as shown in the valida-
tion cohort, higher CRP levels may be associated with
lower SEVR due to increased TTI (that is, afterload (PP)),
presumably induced by the described effect of inflamma-
tion and heart rate acceleration on aortic stiffness.
Another important finding in the current study was that
the SEVR was positively associated with disease duration.
Patients with greater disease duration therefore had better
myocardial perfusion. This finding appears to contradict
the general hypothesis that longer disease duration is asso-
ciated with greater CVD risk [26]. However, a number of
studies have revealed an increased risk for myocardial
infarction within 1 year of RA diagnosis [22,27], and
increased risk of hospitalisation from CVD occurs within
7 years of RA diagnosis [28]. Furthermore, studies utilising
other surrogate measures of coronary endothelial function
have revealed that changes in flow-mediated dilatation
appear to be already evident within 1 year of RA diagnosis
[29], but do not appear to be further influenced by disease
duration [30,31]. Similarly, carotid artery atherosclerosis is
apparent even in patients with a recent diagnosis of RA
[32,33] - and while some studies have found an association
between carotid artery atherosclerosis and longer disease
duration [34,35], other studies have not [36,37]. Collec-
tively, these studies suggest that increased CVD risk is evi-
dent early in the disease course, with reduced risk with
longer disease duration. One possible explanation for
these findings could be that optimal treatment strategies
that effectively control RA symptoms as well as CVD risk
are more likely to be achieved with longer disease dura-
tion, and as a result the patient will have more stable dis-
ease, better myocardial perfusion and lower CVD risk.
Further prospective studies that assess the SEVR in
patients newly diagnosed with RA and who are followed
over the course of their disease are warranted.
The SEVR was found to inversely associate with PP in
the present cohort, but not with MBP. This finding sup-
ports the results of a meta-analysis which revealed that PP
but not MBP was an independent predictor of cardiovas-
cular complications and all-cause mortality in older hyper-
tensive patients [38]. PP is generated by the left ventricle
during systole and is dampened by the compliance of the
aorta. Loss of aortic compliance with age or CVD will lead
to greater PPs, and there is evidence that arterial stiffness
is increased in RA [39]. In addition, conditions such as
hypertension can increase afterload (the pressure the left
ventricle has to overcome to eject blood into the systemic
circulation), which results in increased left ventricular
workload and consequently greater myocardial oxygen
demand, increasing the susceptibility for myocardial
ischaemia [40]. The prevalence of hypertension in RA is
high and the condition is often suboptimally treated [41].
In the present cohort, 44% of patients were hypertensive
but the SEVR did not differ between hypertensive and
nonhypertensive patients. This lack of difference is possi-
bly because the majority of hypertensive patients were on
angiotensin-converting enzyme or angiotensin II subtype-
1 receptor inhibitors as well as b-blockers. Such treatment
increases myocardial perfusion and decreases myocardial
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workload [42], hence making a difference in the SEVR
between hypertensive and nonhypertensive patients unli-
kely. This is supported by our finding that the SEVR was
better in patients receiving b-blockers (compared with
those who were not).
RA patients with diabetes had lower SEVR than non-
diabetic patients, in line with findings from another study
in type 1 diabetics [13]. A number of factors, including
increased glucose levels, can perpetuate damage to the
vasculature in diabetic patients [43], but there is growing
evidence that autonomic dysfunction can adversely alter
heart rate and vascular tone, thereby contributing to
myocardial ischaemia in diabetes [16,44,45]. Importantly,
there is also evidence for autonomic dysfunction in RA
[46], with inflammation being a potential mediating fac-
tor [47]. Given that RA and diabetes have a similar CVD
risk burden [48] and vascular profile [49], further
research examining the role of cardiac autonomic neuro-
pathy on multiple cardiovascular parameters (including
the SEVR) is required.
The strength of the present study is the inclusion of
two separate cohorts of well-characterised RA patients
along with the assessment of a novel and non-invasive
measure of myocardial ischaemia. In addition, the 1-year
prospective study allowed observation of the effect of
anti-inflammatory treatment on the SEVR. Importantly,
the findings were replicated in both cohorts, demonstrat-
ing the strength of the findings. The limitations of the
study include the prospective assessment of the SEVR
following administration of three different types of anti-
inflammatory treatment (anti-TNFa, intravenous corti-
costeroids and rituximab) whose mode of action could
differentially affect the vasculature. However, there was
no difference in parameters of pulse wave analysis
between treatment types at any time point (data not
shown). Another limitation in the prospective arm of the
study was that it was not possible to determine whether
parameters of pulse wave analysis were already impaired
at baseline due to an absence of a healthy control group.
Nevertheless, the average AIx relative to the age of the
prospective cohort would be considered normal, and the
AIx did improve with treatment at 1 year - which tends
to suggest that irreversible vascular alterations were not
evident in this cohort. Finally, the prospective arm of the
study was possibly underpowered to detect a change in
SEVR following treatment; further prospective studies
with a large sample size as well as including a more thor-
ough examination of the factors that affect the ventricu-
lar-vascular coupling are therefore warranted.
Conclusion
In summary, the present study reveals that systemic
markers of inflammation and some classical CVD risk
factors associate with myocardial ischaemia, but further
prospective studies that assess whether the SEVR pre-
dicts future cardiac events in RA and other populations
are warranted.
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